Drug Trial Radar · NCT00699751
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Last checked: Nov 20, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
921
Actual
Start
Jun 12, 2008
Primary completion
Jul 15, 2011
Study completion Feb 13, 2014
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.
Conditions
- Hormone Refractory Prostate Cancer
- Bone Metastases
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)Drug
Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.
PlaceboDrug
Isotonic saline 6 IV administrations separated by 4 weeks intervals.
Best standard of care (BSoC)Drug
Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From randomization to death due to any cause until approximately 3 years after start of enrollment, the data was collected up to the second data analysis date (15 JUL 2011)
Locations
134 sites in 19 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Roseville, California
Site not named
Tampa, Florida
Site not named
New Orleans, Louisiana
Site not named
St Louis, Missouri
Site not named
Las Vegas, Nevada
Site not named
Philadelphia, Pennsylvania
Site not named
Liverpool, New South Wales, Australia
Site not named
Randwick, New South Wales, Australia
Site not named
St Leonards, New South Wales, Australia
Site not named
Sydney, New South Wales, Australia
Site not named
Wahroonga, New South Wales, Australia
Site not named
Wollongong, New South Wales, Australia
Site not named
Herston, Queensland, Australia
Site not named
Toowoomba, Queensland, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Woodville South, South Australia, Australia
Site not named
Hobart, Tasmania, Australia
Site not named
Fitzroy, Victoria, Australia
Site not named
Nedlands, Western Australia, Australia
Site not named
Kortrijk, Belgium
Site not named
Ottignies, Belgium
Site not named
Belo Horizonte, Brazil
Site not named
Salvador, Estado de Bahia, Brazil
Site not named
Belo Horizonte, Minas Gerais, Brazil
Site not named
Rio de Janeiro, Rio de Janeiro, Brazil
Site not named
Porto Alegre, Rio Grande do Sul, Brazil
Site not named
Barretos, São Paulo, Brazil
Site not named
Piracicaba, São Paulo, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
Edmonton, Alberta, Canada
Site not named
London, Ontario, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Brno, Czechia
Site not named
Chomutov, Czechia
Site not named
Olomouc, Czechia
Site not named
Ostrava, Czechia
Site not named
Plzen - Bory, Czechia
Site not named
Prague, Czechia
Showing 40 of 134 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.